Skip to content
Colestilan chloride
BindRen (colestilan chloride) is a small molecule pharmaceutical. Colestilan chloride was first approved as Bindren on 2013-01-21. It has been approved in Europe to treat hyperphosphatemia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AE: Drugs for treatment of hyperkalemia and hyperphosphatemia
— V03AE06: Colestilan
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic renal insufficiencyD051436N181—10——11
HyperphosphatemiaD054559HP_00029051—9——10
DialysisD003956——7——7
DyslipidemiasD050171HP_0003119——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937HP_0003124————11
Alzheimer diseaseD000544EFO_0000249F03————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCOLESTILAN CHLORIDE
INNcolestilan
Description
BindRen (colestilan chloride) is a small molecule pharmaceutical. Colestilan chloride was first approved as Bindren on 2013-01-21. It has been approved in Europe to treat hyperphosphatemia.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID95522-45-5
RxCUI—
ChEMBL IDCHEMBL2103800
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDVSI302RYSR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 53 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
22 adverse events reported
View more details